Search

Zentalis Pharmaceuticals Inc

Atvērts

3.09 -0.96

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.03

Max

3.25

Galvenie mērījumi

By Trading Economics

Ienākumi

-42M

-78M

EPS

-0.59

Darbinieki

106

EBITDA

-42M

-77M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+181.15% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

335K

331M

Iepriekšējā atvēršanas cena

4.05

Iepriekšējā slēgšanas cena

3.09

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 15. sept. 23:56 UTC

Akebia Therapeutics Inc shares are higher in after-market trading. Broader market sentiment is affected by a sharp decline in the NY Empire State Manufacturing Index.

2026. g. 15. sept. 23:56 UTC

Fastly Inc. shares declined after-market, influenced by negative sentiment from the NY Empire State Manufacturing Index's sharp fall. The stock settled lower after a brief recovery.

2026. g. 15. sept. 23:56 UTC

News

Lululemon Athletica shares are lower in after-market hours amid an investigation into potential securities law violations following a revenue guidance cut.

2026. g. 15. sept. 23:56 UTC

eHealth Inc. shares were little changed in after-market hours. Broader market sentiment weakened following a significant decline in the NY Empire State Manufacturing Index.

2026. g. 15. sept. 23:56 UTC

Maxlinear Inc shares are lower in after-market hours, pressured by a sharp decline in the NY Empire State Manufacturing Index, raising economic concerns.

2026. g. 15. sept. 23:56 UTC

DaVita Inc shares are lower in after-market trading amid negative sentiment following a sharp decline in the NY Empire State Manufacturing Index.

2026. g. 15. sept. 23:56 UTC

Textron Inc shares are higher in after-market trading, reaching a peak gain following the NY Empire State Manufacturing Index's sharp decline to 7.6 for September.

2026. g. 15. sept. 23:56 UTC

Bandwidth Inc. shares declined in after-market hours, reflecting negative sentiment tied to a sharp drop in the NY Empire State Manufacturing Index.

2026. g. 15. sept. 23:52 UTC

Japan's August trade deficit hits -1052.6 billion yen amid ongoing economic challenges and weak yen concerns, raising questions on future monetary policy.

2026. g. 15. sept. 23:52 UTC

Japan's Exports Expected to Rise 0.182% YoY Amid Cautious Optimism in Global Trade Dynamics

2026. g. 15. sept. 23:52 UTC

Japan's Machinery Orders Expected to Decline by 2.8% in September, Raising Concerns Over Capital Spending and Business Investment

2026. g. 15. sept. 23:52 UTC

US Business Inventories MoM Data Release on September 16 Expected to Show Modest 0.3% Increase Amid Inflation and Interest Rate Concerns.

2026. g. 15. sept. 23:52 UTC

Brazil's Central Bank to announce interest rate decisions on September 21, amid global focus on central bank policies and inflation concerns.

2026. g. 15. sept. 23:52 UTC

NAHB Housing Market Index for September 2026 Expected at 34.0 Amid Ongoing Builder Confidence Concerns and Slowing Home Construction

2026. g. 15. sept. 23:52 UTC

U.S. Industrial Production Expected to Rise 0.3% in September Amid Mixed Economic Signals and Global Concerns

2026. g. 15. sept. 23:51 UTC

Innovative Industrial Properties Inc shares are higher in after-market hours, though no specific company news was identified to explain the movement.

2026. g. 15. sept. 23:51 UTC

Box Inc shares are higher in after-market hours, continuing a trend of higher closes over the last three sessions. No specific news was identified.

2026. g. 15. sept. 23:51 UTC

Correlated Moves

Shares of Sunrun Inc. declined in after-market trading, diverging from recent trends amid mixed economic data and rising U.S. crude oil inventories.

2026. g. 15. sept. 23:51 UTC

Progressive Corp shares declined during after-market hours, reaching a low of -0.61%. No specific news was identified to explain the price movement.

2026. g. 15. sept. 23:51 UTC

Correlated Moves

Ross Stores Inc shares are higher in after-market trading, reflecting positive sentiment linked to TJX Companies Inc's performance amid increased after-hours activity.

2026. g. 15. sept. 23:51 UTC

CytomX Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement. This marks a shift from recent trends.

2026. g. 15. sept. 23:51 UTC

Under Armour Inc shares are lower in after-market trading, continuing declines amid inflation concerns linked to rising U.S. crude oil inventories.

2026. g. 15. sept. 23:51 UTC

Minerals Technologies Inc shares are lower in after-market hours, with no specific news identified. The stock remains below its 20-day moving average.

2026. g. 15. sept. 23:51 UTC

Editas Medicine Inc shares are higher in after-market trading. No specific company news was identified to explain this price movement.

2026. g. 15. sept. 23:51 UTC

Correlated Moves

Raymond James Financial shares are higher in after-market trading, aligning with Bank of America's performance despite mixed broader market sentiment.

2026. g. 15. sept. 23:51 UTC

T-Mobile US Inc shares are higher in after-market hours, continuing a recent upward trend from earlier lows. No specific news was identified for the movement.

2026. g. 15. sept. 23:46 UTC

Insight Enterprises Inc shares are higher in after-market trading, advancing slightly since Tuesday's close. The stock is positioned above its 20-day moving average.

2026. g. 15. sept. 23:46 UTC

California Water Service Group shares were roughly flat in after-market hours, remaining about 3.74% below their 20-day moving average.

2026. g. 15. sept. 23:46 UTC

LeMaitre Vascular Inc. shares are higher in after-market trading, moving within a narrow range since Tuesday's close and remaining near the lower end of their monthly range.

2026. g. 15. sept. 23:46 UTC

Essential Utilities Inc shares are higher in after-market hours, remaining near the upper end of their one-month trading range. No specific news was identified.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

181.15% augšup

Prognoze 12 mēnešiem

Vidējais 8.8 USD  181.15%

Augstākais 11 USD

Zemākais 5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

5

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat